Treatment of congenital nephrogenic diabetes insipidus with fluconazole, an antifungal medication

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517438-16-00

Enrollment

Registered

2024-09-12

Start date

2024-09-12

Completion date

Unknown

Last updated

2025-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephrogenic diabetes insipidus

Brief summary

Spontaneous urinary volume and urinary concentration ability (osmolality).

Detailed description

Plasma osmolality, abundance of AQP2 in urinary exosomes, plasma vasopressin/copeptin concentrations, plasma electrolytes, micturition frequency

Interventions

DRUGFLUCONAZOLE

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Spontaneous urinary volume and urinary concentration ability (osmolality).	—

Secondary

Measure	Time frame
Plasma osmolality, abundance of AQP2 in urinary exosomes, plasma vasopressin/copeptin concentrations, plasma electrolytes, micturition frequency	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026